The US Department of Justice said on Wednesday it had dropped its legal action against Ranbaxy after the the Indian generic drugs maker stepped up co-operation over regulators’ concerns about its manufacturing.

Ranbaxy’s shares jumped almost 10 per cent, having long been depressed by escalating investigations from the US Food and Drug Administration, triggering a ban, which is still in place, that stops the US importing or purchasing the company’s drugs.